Several STAT3 inhibitors have also entered clinical trials for obesity-linked cancers, including pancreatic cancer (phase III), metastatic colorectal cancer (phase II), ovarian cancer (phase II), hepatocellular carcinoma (phase I), and breast cancer (phase I) (37). Here, STAT3 is linked to ovarian carcinoma.